Hostname: page-component-669899f699-vbsjw Total loading time: 0 Render date: 2025-04-24T14:11:58.822Z Has data issue: false hasContentIssue false
  • English
  • Français

A review of the efficacy and tolerability of venlafaxine

Published online by Cambridge University Press:  16 April 2020

M Dierick
M Dierick*
Affiliation:
Sint Camillus Psychiatric Hospital, Sint Denijs-Westrem, Wittepaalstraat, 12 B-9051, Afsnee, Belgium
Get access

Summary

Venlafaxine is a selective serotonin norepinephrine reuptake inhibitor with no activity at muscarinic, histaminergic or adrenergic receptors. The antidepressant activity of venlafaxine has been demonstrated in placebo-controlled and active comparator-controlled clinical trials. Venlafaxine was effective in outpatients and hospitalized patients with major depression and in those with melancholia, agitated or retarded symptoms, and refractory or treatment-resistant depression. Venlafaxine was at least as effective as comparative antidepressants and was more effective than fluoxetine or imipramine in some trials. A positive dose-response relationship has been shown with venlafaxine. When doses of venlafaxine are titrated rapidly upward, an onset of antidepressant action has been detected within one week in some studies. Venlafaxine is well tolerated during short- and long-term treatment. The most common adverse effects are nausea, somnolence and dry mouth. The overall tolerability of venlafaxine appears to exceed that of tricyclic antidepressants and compares favorably with that of selective serotonin reuptake inhibitors. Venlafaxine is a novel antidepressant that is appropriate for first-line therapy in patients with major depression.

Keywords

venlafaxinemajor depressiontricyclicsSSRIs
Type
Research Article
Information
European Psychiatry , Volume 12 , Issue S4 , 1997 , pp. 307s - 313s
Copyright
Copyright © Elsevier, Paris 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Bech, PA review of the antidepressant properties of serotonin reuptake inhibitors. Adv Biol Psychiatry 1988; 17: 58–69CrossRefGoogle Scholar
Beasley, CM Jr, Bosomworth, JC, Wernicke, JFFluoxetine: relationship among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull 1990; 26: 18–24Google ScholarPubMed
Benkert, O, Gründer, G, Wetzel, H, Hackett, DA randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 1996; 30: 441–451CrossRefGoogle ScholarPubMed
Bergstrom, RF, Peyton, AL, Lemberger, LQuantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992; 51: 239–248CrossRefGoogle ScholarPubMed
Clerc, GE, Ruimy, P, Verdeau-Pailles, Jon behalf of the Venlafaxine French Inpatient Study Group A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994; 9: 139–143CrossRefGoogle ScholarPubMed
Cunningham, LA, Borison, RL, Carman, JSet al.A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994; 14: 99–106CrossRefGoogle ScholarPubMed
Depression Guideline Panel AHCPR Publication NO 93-0551 Depression in Primary Care: Volume 2. Treatment of Major Depression. Clinical Practice Guideline Number 5. Rockville, MD. US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research AHCPR publication No 93-0551, April 1993Google Scholar
Dierick, M, Ravizza, L, Realini, R, Martin, AA double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 57–71CrossRefGoogle ScholarPubMed
Dunner, DL, Dunbar, GCOptimal dose regimen for paroxetine. J Clin Psychiatry 1992; 53: 21–26Google ScholarPubMed
Entsuah, R, Upton, GV, Rudolph, REfficacy of venlafaxine treatment in depressed patients with psychomotor retardation or agitation: A meta-analysis. Hum Psychopharmacology 1995; 10: 195–200CrossRefGoogle Scholar
Ferguson, J, Khan, A, Kucharik, Ret al.A placebo-controlled comparative study of the effects of blood pressure and antidepressant efficacy of venlafaxine and imipramine (suppl) Neuropsychopharmacology 1994; 10: 165Google Scholar
Gründer, G, Wetzel, H, Schlosser, R, Benkert, OSubchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24 hour monitoring. Pharmacopsychiatry 1996; 29: 73–78CrossRefGoogle ScholarPubMed
Guelfi, JD, White, C, Hackett, Det al.Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995; 56: 450–458Google ScholarPubMed
Khan, A, Rudolph, R, Baumel, Bet al.Venlafaxine in depressed geriatric outpatients: an open-label clinical study. Psychopharmacol Bull 1995; 31: 753–758Google ScholarPubMed
Lecable, P, Letzelter, J-M, Lichtblau, Eet al.An open label evaluation of the clinical acceptability of venlafaxine for general use as an antidepressant. Prim Care Psychiatry 1995; 1: 45–51Google Scholar
Magni, G, Hackett, DAn open-label evaluation of the long-term safety and clinical acceptability of venlafaxine in depressed patients (abstract). Clin Neuropharmacology 15 (suppl 1, Pt B) 1992 323BCrossRefGoogle Scholar
Mendels, J, Johnston, R, Mattes, J, Riesenberg, REfficacy and safety of bid doses of venlafaxine in a dose-response study. Psychopharmacol Bull 1993; 29: 169–174Google Scholar
Mendlewicz, JPharmacologic profile and efficacy of venlafaxine. Int Clin Psychopharmacol 10suppl 21995 5–14CrossRefGoogle ScholarPubMed
Michels, R, Marzuk, PMProgress in psychiatry. N Engl J Med 1993; 329: 628–638CrossRefGoogle Scholar
Muth, EA, Haskins, JT, Moyer, JAet al.Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986; 35: 4493–4497CrossRefGoogle ScholarPubMed
Muth, EA, Moyer, JA, Haskins, JTet al.Biochemical, neurophysiological, and behavioral effects of Wy-45, 233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991; 23: 191–199CrossRefGoogle Scholar
Nierenberg, A, Feighner, JP, Rudolph, Ret al.Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994; 14: 19–423CrossRefGoogle ScholarPubMed
Otton, SV, Ball, SE, Cheung, SWet al.Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996; 41: 149–156CrossRefGoogle ScholarPubMed
Preskom, SH, Lane, RMSertraline 50 mg: optimal dose in the treatment of depression. Int Clin Psychopharmacology 1995; 10: 129–141CrossRefGoogle Scholar
Preskorn, SHAntidepressant drug selection: criteria and options. J Clin Psychiatry 55 (suppl) 1994 6–21Google ScholarPubMed
Rudolph, R, Entsuah, R, Derivan, AEarly clinical response in depression to venlafaxine hydrochloride (abstract). Biol Psychiatry 1991; 29: 630SGoogle Scholar
Rudolph, R, Entsuah, R, Derivan, AA low relapse rate confirms the long-term efficacy of venlafaxine in the treatment of major depression (abstract). Neuropsychopharmacology 1994 10 (suppl) 105Google Scholar
Rudorfer, MV, Potter, WZAntidepressants: a comparative review of the clinical pharmacology and therapeutic use of the ‘newer’ versus the ‘older’ drugs. Drugs 1989; 37: 713–738CrossRefGoogle ScholarPubMed
Samuelian, JC, Tatossian, A, Hackett, DA randomized, double-blind, parallel group comparison of venlafaxine and clomipramine in outpatients with major depression (abstract). Clin Neuropharmacology 15 (Suppl 1, Pt B) 1992 324BCrossRefGoogle Scholar
Schweizer, E, Feighner, JP, Mandos, LA, Rickels, KComparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994; 55: 104–108Google ScholarPubMed
Shrivastava, R, Cohn, C, Crowder, Jet al.Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 1994; 14: 322–329CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.